Overview

A Novel Anti-Obesity Drug Combination as a Pharmacotherapy for Cocaine Dependence

Status:
Completed
Trial end date:
2018-06-01
Target enrollment:
Participant gender:
Summary
The research proposed in this application will determine the initial efficacy, safety and tolerability of a novel drug combination, bupropion and naltrexone, as a pharmacotherapy for cocaine dependence. A rigorous, inpatient human laboratory study will be conducted. The proposed study is innovative and important because it will provide the impetus for the conduct of double blind, placebo-controlled trials to further demonstrate the efficacy of bupropion-naltrexone combinations for managing cocaine dependence.
Phase:
Early Phase 1
Details
Lead Sponsor:
Craig Rush
Collaborator:
National Institute on Drug Abuse (NIDA)
Treatments:
Bupropion